Study summary

An antifibrotic pill slowed lung function decline in limited scleroderma too

SENSCIS analysis (nintedanib) · Phase 3 subgroup analysis · Published March 2024, Rheumatology; FDA approved for SSc-ILD 2019

What was tested

Nintedanib, an antifibrotic pill approved for idiopathic pulmonary fibrosis, against placebo, in people with limited cutaneous systemic sclerosis and lung disease.

What they found

• Lung capacity declined 49.1 ml a year vs 74.5 ml with placebo.
• The benefit continued in the open-label extension.

What it means

Shows the lung benefit applies across scleroderma subtypes.